Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC.
Byoung Chul ChoShun LuEnriqueta FelipAlexander I SpiraNicolas GirardJong-Seok LeeSe-Hoon LeeYurii OstapenkoPongwut DanchaivijitrBaogang LiuAdlinda AlipErnesto KorbenfeldJosiane Mourão DiasBenjamin BesseKi-Hyeong LeeHailin XiongSoon-Hin HowYing ChengGee-Chen ChangHiroshige YoshiokaJames C-H YangMichael ThomasDanny NguyenSai-Hong I OuSanjay MukhedkarKumar PrabhashManolo D'ArcangeloJorge Alatorre-AlexanderJuan C Vázquez LimónSara AlvesDaniil StroyakovskiyMarina PeregudovaMehmet A N ŞendurOzan YaziciRaffaele CalifanoVanesa Gutiérrez CalderónFilippo de MarinisAntonio PassaroSang-We KimShirish M GadgeelJohn XieTao SunMelissa MartinezMariah EnnisElizabeth FennemaMahesh DakshDawn MillingtonIsabelle LeconteRyota IwasawaPatricia LorenziniMahadi BaigSujay ShahJoshua M BaumlS Martin ShreeveSeema SethiRoland E KnoblauchHidetoshi Hayashinull nullPublished in: The New England journal of medicine (2024)
-mutated advanced NSCLC. (Funded by Janssen Research and Development; MARIPOSA ClinicalTrials.gov number, NCT04487080.).